Technologies and Mechanisms for Oral Modified Release by Monolithic and Multiparticulate Delivery Systems
Abstract
Innovation in oral drug delivery is focusing more and more on patient adherence to therapy. Drug combination with MR monolithic formulations requires the intake of several tablets each containing the specific drug. Concerning their biopharmaceutical properties, the small size of multiparticulates reduces their effect on gastrointestinal transit compared to modified release (MR) monoliths. Drug release from MR multiparticulate systems, in particular pellets, matches the drug release kinetics for monolithic or reservoir systems. Pellets are produced via a plethora of manufacturing methods. Extrusion–spheronization is probably the most common process for the industrial production of pellets. The technologies and applications demonstrate that multiparticulate drug delivery systems for MR are worthy of further research for the development of new medicinal products. Multiparticulate technologies enable line extensions or re-positioning for already marketed oral drugs, particularly to improve bioavailability while also trying to respond to the need for patient-centric formulations.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.